



Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
Cyber One, Unit No. 902, Sector 30A,
Plot No - 4 & 6, Vashi,
Navi Mumbai - 400703, India
T: +91 22 2789 2924
F: +91 22 2789 2942

Date: January 14, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

BSE Security Code: 544292

National Stock Exchange of India Limited
Exchange Plaza, 5th floor, Plot No. - C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
NSE Symbol: ONESOURCE

Dear Sir/ Madam,

Sub: Disclosure under regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Amalgamation of Stelis Pte. Limited with OneSource Specialty Pte. Limited, wholly owned subsidiaries of OneSource Specialty Pharma Limited (“the Company”).

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“**SEBI Listing Regulations**”), it is to inform that Stelis Pte. Limited, a wholly owned subsidiary of the Company, has been amalgamated with OneSource Specialty Pte. Limited, another wholly owned subsidiary of the Company. Both the Companies are incorporated in Singapore.

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a disclosure as Annexure A to this letter.

Please take the information on record.

For OneSource Specialty Pharma Limited

Trisha A
Company Secretary & Compliance Officer
Membership Number: A47635

Details and disclosure of the Scheme of Amalgamation under Regulation 30 of the SEBI Listing Regulations

Annexure A

Sr. No.	Particulars	Details
1.	Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.;	<p>Stelis Pte. Limited (“Stelis”) a wholly owned subsidiary of the Company amalgamated with Onesource Specialty Pte. Limited (“Onesource Specialty Pte.”) another wholly owned subsidiary of the Company with effect from January 01, 2026. Both Stelis and Onesource Specialty Pte. are incorporated in Singapore.</p> <p>The turnover of Stelis and Onesource Specialty for the financial year ended 31st March 2025 is USD 7.86 million and USD 34.09 million respectively.</p>
2.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms’ length”;	<p>The transaction is undertaken between the wholly owned subsidiaries of the Company and accordingly there is no impact on a consolidated basis.</p> <p>As per the provisions of Section 188 of Companies Act, 2013 and Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provisions relating to related party transactions are not applicable in respect of transactions between wholly owned subsidiaries of a holding company.</p>
3	Area of business of the entity(ies);	<p>Stelis is engaged in the business of manufacturing of pharmaceutical products and preparations for human use.</p> <p>Onesource Specialty Pte. is engaged in the business developing, marketing, and distributing pharmaceutical goods, including injectables, for various markets.</p>
4	Rationale for amalgamation/merger;	The Company proposed to consolidate Stelis with Onesource Specialty Pte. to simplify the existing corporate hierarchy to enhance operational efficiency and eliminate redundant administrative, compliance, and legal costs.
5	In case of cash consideration – amount or otherwise share exchange ratio;	The shares of Stelis held by the Company will be cancelled and shares in Onesource Specialty Pte. will be issued to the Company.

Onesource

Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
Cyber One, Unit No. 902, Sector 30A,
Plot No - 4 & 6, Vashi,
Navi Mumbai - 400703, India
T: +91 22 2789 2924
F: +91 22 2789 2942

6	Brief details of change in Shareholding pattern (if any) of listed entity.	The proposed amalgamation is between the wholly owned subsidiaries of the Company and, accordingly, there is no impact on the shareholding pattern of the Company.
---	---	--

For OneSource Specialty Pharma Limited

Trisha A
Company Secretary & Compliance Officer
Membership Number: A47635

